Printer Friendly

CANTAB PHARMACEUTICALS SIGNS AGREEMENT WITH OXFORD UNIVERSITY AND REPORTS ON COLLABORATION WITH UNIVERSITY COLLEGE LONDON

 CAMBRIDGE, England, May 4 /PRNewswire/ -- Cantab Pharmaceuticals plc (NASDAQ: CNTBY) today announced that it has signed a two-year agreement with the University of Oxford. The agreement gives Cantab an option to acquire rights to certain inventions in the area of T-cell receptors for human therapy. Cantab's scientists will assist with the identification and protection of proprietary products and technology emerging from research carried out in some of the University's clinical research laboratories.
 The agreement allows Cantab to assist certain University researchers in filing patent applications relating to their inventions and in return will gain options to commercialize this technology. Where Cantab decides to proceed with commercial development of technology patented in this way the University will receive fees and royalties.
 "We believe that this relationship will benefit the University and Cantab by enhancing the commercial value of both organizations' research," said Paul Haycock, M.D., president and chief executive officer of Cantab. "Cantab now has relationships with two of the premier universities in the United Kingdom. We look forward to working with the Oxford researchers and expect to expand our product and technology portfolio over the next two years."
 Cantab also reported results of its research program to identify new products for the treatment of Crohn's disease and other inflammatory bowel diseases. Research conducted by Cantab scientists in collaboration with St. Bartholomew's Centre for Clinical Research, London and University College London previously has focused on the evaluation of a monoclonal antibody, called LM-IBD1, that blocks damage of intestinal tissue in a disease model. "The results of our research on mode of action of the LM-IBD1 antibody show that a more selective antibody will be needed to form the basis of a therapy for Crohn's disease" said Dr. Alan Munro, chief scientific officer of Cantab. "Consequently, we have decided to stop preclinical development of the LM-IBD1 antibody and this allows us to refocus our research collaboration with St. Bartholomew's and University College scientists to make and screen new monoclonal antibodies to identify more specific drug candidates."
 Cantab is engaged in the research and development of biopharmaceuticals that use the highly selective properties of the immune system to treat disease. The company has research and development programs in two principal areas: Leucocyte Modulators, which regulate or block immune system function, and Therapeutic Antigens, which activate specific immune responses. Cantab's initial therapeutic focus includes research programs in the prevention of organ transplant rejection, the treatment of Crohn's disease and cervical cancer as well as work on genital herpes.
 -0- 5/4/93
 /CONTACT: Paul Haycock, M.D. (United Kingdom) of Cantab Pharmaceuticals plc, 011-44-223-423413, Georgina Ferry, press officer of the University of Oxford, 011-44-865-278182, Dr. Jim Shedden of UCLi Limited (University of London), 011-44-71-636-7668, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, 212-979-9180, for Cantab Pharmaceuticals/
 (CNTBY)


CO: Cantab Pharmaceuticals plc ST: IN: MTC SU:

PS-OS -- NY023 -- 4200 05/04/93 09:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1993
Words:483
Previous Article:SOUTHWESTERN BELL CORPORATION AND COX CABLE COMMUNICATIONS FINALIZE U.K. PARTNERSHIP AGREEMENT
Next Article:AMBER'S STORES SALES UP 52 PERCENT IN APRIL
Topics:


Related Articles
CANTAB, BAXTER EXPAND COLLABORATION ON LM-CD45 ANTIBODY TO PREVENT ORGAN TRANSPLANT REJECTION
BAXTER, CANTAB EXPAND COLLABORATION ON ANTI-CD45 ANTIBODY TO PREVENT ORGAN-TRANSPLANT REJECTION
CANTAB EXPANDS INFLAMMATORY DISEASE PROGRAM THROUGH STANFORD UNIVERSITY COLLABORATION
OXFORD MOLECULAR GROUP ANNOUNCES COLLABORATIVE RESEARCH AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
OXFORD MOLECULAR GROUP AND ALIZYME SIGN DRUG DISCOVERY PROGRAM FOR OBESITY
OXFORD MOLECULAR GROUP SIGNS SECOND PROTEIN DESIGN COLLABORATION WITH NEORX CORP.
CANTAB AND SMITHKLINE BEECHAM FORM VACCINE COLLABORATION
Oxford Molecular Group and PolyMASC Sign Drug Design Collaboration
Oxford Molecular Signs Deals with University of Washington and Southwest Parallel Software
Cantab Agrees Terms with Glaxo Wellcome for Disc HSV Prophylactic Vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters